The discovery of SGLT2 inhibitors, with novel mechanism independent of insulin secretion or sensitization, may possibly expand the armamentarium in the battle against type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.